Dissemin is shutting down on January 1st, 2025

Published in

MDPI, Journal of Clinical Medicine, 7(9), p. 2142, 2020

DOI: 10.3390/jcm9072142

Links

Tools

Export citation

Search in Google Scholar

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives

Journal article published in 2020 by Roberto Mina ORCID, Stefania Oliva ORCID, Mario Boccadoro
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival. Several techniques are available for the detection of MRD inside (next-generation sequencing, flow cytometry) and outside (PET/CT, magnetic resonance) the bone marrow, and their complementary use allows a precise definition of the efficacy of anti-myeloma treatments. This review summarizes MRD data and results from previous clinical trials, highlights open issues related to the role of MRD in MM and discusses how MRD could be implemented in clinical practice to inform on patient prognosis and drive therapeutic decisions.